Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms

Affiliations

¹ Department of Obstetrics and Gynecology, Division of Midlife Health, University of Charlottesville, Charlottesville, VA 22908, USA.
² Department of Obstetrics and Gynecology Division of Minimally Invasive Gynecologic Surgery, University of Virginia, Charlottesville, VA, USA.
³ Department of Obstetrics and Gynecology, University of Florida College of Medicine- Jacksonville, Jacksonville, FL, USA.

Editorial

JoAnn V Pinkerton et al. J Clin Endocrinol Metab. 2023.

. 2023 Oct 18;108(11):e1448-e1449.

doi: 10.1210/clinem/dgad209.

¹ Department of Obstetrics and Gynecology, Division of Midlife Health, University of Charlottesville, Charlottesville, VA 22908, USA.
² Department of Obstetrics and Gynecology Division of Minimally Invasive Gynecologic Surgery, University of Virginia, Charlottesville, VA, USA.
³ Department of Obstetrics and Gynecology, University of Florida College of Medicine- Jacksonville, Jacksonville, FL, USA.

No abstract available

Keywords: KNDy; fezolinetant; neurokinin 3 receptor antagonist; nonhormonal; vasomotor symptoms.

Comment on

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N. Johnson KA, et al. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-1997. doi: 10.1210/clinem/dgad058. J Clin Endocrinol Metab. 2023. PMID: 36734148 Free PMC article. Clinical Trial.

1. Johnson KA, Martin N, Nappi RE, et al. . Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023;108(8):1981-1997. Doi: 10.1210/clinem/dgad058 - DOI - PMC - PubMed
1. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. 2009;62(2):153‐159. Doi: 10.1016/j.maturitas.2008.12.006 - DOI - PubMed
1. Kaunitz AM, Kapoor E, Faubion S. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause. JAMA. 2021;326(14):1429‐1430. Doi: 10.1001/jama.2021.3305 - DOI - PMC - PubMed
1. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211‐227. Doi: 10.1016/j.yfrne.2013.07.003 - DOI - PMC - PubMed
1. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681‐694. Doi:10.1080/13543784.2021.1893305 - DOI - PubMed